InflaRx N.V.
NASDAQ:IFRX · NASDAQ Global Select
-$0.02 today
Vol 1.46M · Avg 1.80M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-109.9%
avg -34.0%
ROIC
-113.6%
avg -54.9%
ROA
-82.7%
avg -48.4%
Analysis
ROA is currently the strongest return metric at -82.7% versus its period average of -48.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter Hurt | Senior Director and Head of Drug Safety & Pharmacovigiliance | — | — | — | — | — |
Kirsten Cremering | Senior Director & Head of Quality Assurance | — | — | — | — | — |
Nicole Bertsch | Senior Director & Head of Human Resources | — | — | — | — | — |
Niels C. Riedemann | Co-Founder, Chief Executive Officer & Executive Director | — | — | 53 | $1.07M | 1.48% |
Renfeng Guo | Co-Founder, Chief Scientific Officer & Executive Director | — | — | 56 | — | — |
Derval O'Carroll | Senior Vice President and Global Head of Regulatory Affairs & Compliance | — | — | 60 | $0.00 | <0.01% |
Camilla Chong | Chief Medical Officer | — | — | 60 | — | — |
Igor Orshanskiy | Senior Director & Head of Business Development | — | — | — | — | — |
Maria Habel | Vice President, Head of Preclinical R&D and QC | — | — | 44 | — | — |
Thomas Taapken | Chief Financial Officer | — | — | 61 | $3,500.00 | <0.01% |
Christian Schmid | Vice President and Head of Legal Affairs & General Counsel | — | — | — | — | — |
Jan Medina | Head of Investor Relations & Vice President | — | — | — | — | — |
Kofi Boaten | VP and Head of Supply Quality & Clinical Trial Supplies | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$283.06M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$234.93M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.33M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.61M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.77M
ImageneBio Inc
NASDAQ:IMA
$68.52M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.81M
Metagenomi, Inc. Common Stock
MGX
$45.93M
aTyr Pharma, Inc.
ATYR
$45.03M
Quince Therapeutics, Inc.
QNCX
$5.03M
Who manages IFRX?
InflaRx N.V. (IFRX) lists 13 active executives. The top listed executive is Peter Hurt, Senior Director and Head of Drug Safety & Pharmacovigiliance.
Are IFRX insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.